Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13569513 | 1.00 | MAPT (0.49) | MAPTKDM4EHIF1ASLC22A6SLC22A8 | |
| SCHEMBL2801369 | 0.82 | MAPT (0.45) | MAPTKDM4EHIF1ACA1CA2 | |
| SCHEMBL4259258 | 0.82 | ALDH1A1 (0.41) | ALDH1A1EPHX2NR1H4 | |
| SCHEMBL4259261 | 0.82 | ALDH1A1 (0.41) | ALDH1A1EPHX2NR1H4 | |
| SCHEMBL4259268 | 0.82 | ALDH1A1 (0.41) | ALDH1A1EPHX2NR1H4 | |
| SCHEMBL13232832 | 0.80 | EGFR (0.48) | MAPTALDH1A1KMT2A | |
| SCHEMBL2798947 | 0.80 | EGFR (0.48) | MAPTALDH1A1KMT2A | |
| SCHEMBL2801170 | 0.79 | FBP1 (0.50) | MAPTCA1CA2ALDH1A1KMT2A | |
| SCHEMBL4261335 | 0.79 | FBP1 (0.50) | MAPTCA1CA2ALDH1A1KMT2A | |
| SCHEMBL4261334 | 0.79 | FBP1 (0.50) | MAPTCA1CA2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | WEINER, CARL P | 2009-12-24 | — | — | US | claimed |
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | WEINER, CARL P | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | GPX1, SOD1, GPX4 | MAPT 3911/4885KDM4E 4059/4885HIF1A 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.